Regeneron and Sanofi announced that a late-stage trial for the blockbuster anti-inflammatory drug Dupixent for patients with chronic spontaneous urticaria (CSU) was halted due to futility.
Alexion, the unit within global pharmaceutical firm AstraZeneca that focuses on finding treatments for rare diseases, is halting clinical trials for Ultomiris (ravulizumab) for adults with amyotrophic lateral sclerosis.
Germany’s CureVac is on track to file for European approval of the company’s Covid-19 vaccine as early as this month because high infection rates among trial participants are bringing a read-out on efficacy within closer reach. The group’s late-stage trial involves more than 37,000 volunteers in Europe and Latin America, half of whom are receiving a placebo.
As a massive Covid-19 surge continues to rage on throughout India, scientists and public health officials scramble to determine whether currently authorized vaccines in the country can provide a mitigation effect to this unprecedented spread. A new study published online has provided some hope, with researchers suggesting that the Covaxin vaccine – developed by Bharat Biotech and Pennsylvania-based Ocugen – could neutralize the SARS-CoV-2 variant leading the second wave in India.
Treating Covid-19 patients at home with a commonly used inhaled asthma drug called budesonide can speed up their recovery, according to UK trial results on April 12 which doctors said could change the way the disease is treated around the world.
Shares of Mesoblast Limited were down more than 30% in trading following the company’s disappointing announcement regarding a stem-cell therapy trial in ventilator-dependent patients with Covid-19 patients who have moderate-to-severe acute respiratory distress syndrome.
Moderna Inc. applied for U.S. emergency authorization for the company’s Covid-19 vaccine after full results from a late-stage study showed mRNA-1273 was 94.1% effective with no serious safety concerns.
Moderna announced plans to submit the company’s request to the U.S. Food and Drug Administration for an Emergency Use Authorization (EUA) for the Covid-19 vaccine mRNA-1273 on Nov. 30.
Clene Nanomedicine is trying to set a new “gold standard” in neurodegenerative diseases through the development of a new class of drugs called bioenergetic nanotherapeutics that harnesses the properties of gold nanocrystals.
Immunocore’s Phase III IMCgp100-202 trial of tebentafusp compared to investigator’s choice for metastatic uveal melanoma (mUM) met the pre-defined boundaries for statistical significance of the primary endpoint of overall survival in its first pre-planned interim analysis.
